0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Systemic and Intracerebral Administration of Two Opposite Acting ACTH-Related Peptides on Extinction of Conditioned Avoidance Behavior

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effects of the decapeptide ACTH-(1–10) and [D-phe<sup>7</sup>]-ACTH-(1–10) were tested on the rate of extinction of a pole-jumping avoidance response in rats. ACTH-(1–10) in doses of 20, 50, and 100 µg inhibited extinction of the avoidance response 4 h following subcutaneous administration. [D-phe<sup>7</sup>]-ACTH-(1–10) in doses of 20, 50, and 100 µg facilitated extinction 4 h after injection. Intracerebral implantation of approximately 10 µg of these ACTH-analogues in the freely moving rat had similar effects on extinction of avoidance response when implanted into the region of the rostral mesencephalon and the caudal diencephalon, at the posterior thalamic level, or in the cerebrospinal fluid. Ineffective sites were the nucleus ventralis thalami, the nucleus anterior medialis thalami, the nucleus reuniens, the globus pallidus, the nucleus accumbens, the fornix, and the hippocampus. The results support the hypothesis that the site of action of ACTH and of ACTH-analogues on extinction of an avoidance response is localized in the central nervous system.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1971
          1971
          19 March 2008
          : 7
          : 5-6
          : 291-301
          Affiliations
          Rudolf Magnus Institute for Pharmacology, Medical Faculty, University of Utrecht, Utrecht
          Article
          121977 Neuroendocrinology 1971;7:291–301
          10.1159/000121977
          4326088
          © 1971 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Categories
          Paper

          Comments

          Comment on this article